FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892016776> ?p ?o ?g. }

• W2892016776 abstract "e17058 Background: Dose-dense chemotherapy is increasingly more utilized in the adjuvant treatment of patients (pts) with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), as compared to the conventional q3 week chemotherapy regimen. The safety and tolerability of the dose-dense regimen in pts ≥65 yrs old has not been well studied. We performed a retrospective analysis of pts with stage II-IV EOC treated at our institution with either regimen. Methods: We identified pts with stage II-IV EOC treated at Northwell Health from 2010-2015 who received adjuvant chemotherapy with the dose-dense (carboplatin q3 weeks/weekly paclitaxel) or the conventional (carboplatin and paclitaxel q3 weeks) regimen. Pts who received IP chemotherapy were excluded. Demographics, adverse events (AEs), dose delays/reductions and efficacy outcomes were evaluated. Results: 38 pts received conventional chemotherapy (median age 68 yrs) and 29 pts received dose-dense chemotherapy (median age 61 yrs). There were no differences in the frequency of grade ≥3 hematologic toxicities b/w the two arms. There were no differences in delayed or missed doses between the two arms but a higher proportion of dose reductions in the dose-dense arm ( P= 0.0472). Among pts treated in the dose-dense arm, 87.5% of women < 65 yrs old had at least one grade ≥3 AE when compared to 38.5% of women ≥ 65 yrs old ( P= 0.0161). There were no differences in dose delays, dose reductions, or missed doses when compared by age in the dose-dense arm. In the dose-dense arm, stage III-IV pts < 65 yrs old had a median time to progression (TTP) of 13.0 mo (95% CI, 6.7-13.8) and a median overall survival (OS) of 48.3 months (95% CI, 11.5-48.3). Pts ≥ 65 yrs old had a median TTP of 10.9 mo (95% CI, 8.7-12.7) and median OS of 35.9 mo (95% CI, 30.8-not reached). There was no difference in TTP ( P= 0.2154) or OS ( P= 0.9260) between the two cohorts. Conclusions: Our institutional experience of administering dose-dense adjuvant chemotherapy to women with EOC suggests that this regimen is likely safe in women ≥ 65 yrs old, with similar efficacy outcomes and should be considered for this population. Further study with larger sample sizes and in prospective trials is warranted." @default.
• W2892016776 created "2018-09-27" @default.
• W2892016776 creator A5001521114 @default.
• W2892016776 creator A5013920996 @default.
• W2892016776 creator A5027545003 @default.
• W2892016776 creator A5028283090 @default.
• W2892016776 creator A5030166341 @default.
• W2892016776 creator A5033548794 @default.
• W2892016776 creator A5043930576 @default.
• W2892016776 creator A5058245063 @default.
• W2892016776 creator A5062848476 @default.
• W2892016776 creator A5062934634 @default.
• W2892016776 creator A5081519165 @default.
• W2892016776 creator A5089453381 @default.
• W2892016776 date "2017-05-20" @default.
• W2892016776 modified "2023-09-23" @default.
• W2892016776 title "Safety and efficacy outcomes for patients ages 65 and older treated with dose-dense chemotherapy for epithelial ovarian cancer." @default.
• W2892016776 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e17058" @default.
• W2892016776 hasPublicationYear "2017" @default.
• W2892016776 type Work @default.
• W2892016776 sameAs 2892016776 @default.
• W2892016776 citedByCount "0" @default.
• W2892016776 crossrefType "journal-article" @default.
• W2892016776 hasAuthorship W2892016776A5001521114 @default.
• W2892016776 hasAuthorship W2892016776A5013920996 @default.
• W2892016776 hasAuthorship W2892016776A5027545003 @default.
• W2892016776 hasAuthorship W2892016776A5028283090 @default.
• W2892016776 hasAuthorship W2892016776A5030166341 @default.
• W2892016776 hasAuthorship W2892016776A5033548794 @default.
• W2892016776 hasAuthorship W2892016776A5043930576 @default.
• W2892016776 hasAuthorship W2892016776A5058245063 @default.
• W2892016776 hasAuthorship W2892016776A5062848476 @default.
• W2892016776 hasAuthorship W2892016776A5062934634 @default.
• W2892016776 hasAuthorship W2892016776A5081519165 @default.
• W2892016776 hasAuthorship W2892016776A5089453381 @default.
• W2892016776 hasConcept C121608353 @default.
• W2892016776 hasConcept C126322002 @default.
• W2892016776 hasConcept C143998085 @default.
• W2892016776 hasConcept C2776694085 @default.
• W2892016776 hasConcept C2780427987 @default.
• W2892016776 hasConcept C2992773878 @default.
• W2892016776 hasConcept C71924100 @default.
• W2892016776 hasConceptScore W2892016776C121608353 @default.
• W2892016776 hasConceptScore W2892016776C126322002 @default.
• W2892016776 hasConceptScore W2892016776C143998085 @default.
• W2892016776 hasConceptScore W2892016776C2776694085 @default.
• W2892016776 hasConceptScore W2892016776C2780427987 @default.
• W2892016776 hasConceptScore W2892016776C2992773878 @default.
• W2892016776 hasConceptScore W2892016776C71924100 @default.
• W2892016776 hasLocation W28920167761 @default.
• W2892016776 hasOpenAccess W2892016776 @default.
• W2892016776 hasPrimaryLocation W28920167761 @default.
• W2892016776 isParatext "false" @default.
• W2892016776 isRetracted "false" @default.
• W2892016776 magId "2892016776" @default.
• W2892016776 workType "article" @default.